The safety and efficacy of AHCC for pulmonary MAC disease

The safety and efficacy of AHCC for pulmonary MAC disease - AHCC for pulmonary MAC disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020822

Enrollment

Registered

2016-02-10

Start date

2016-02-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary MAC disease

Interventions

Active Hexose Correlated Compound (AHCC) AHCC 1800mg/day (600mg x 3 times) At least 2 weeks, at maximum 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Informed consent attained (2) Treatble case for pulmonary MAC disease (3) Age above 20 years old (4) Confirmed diagnosis of pulmonay MAC diseases

Exclusion criteria

Exclusion criteria: (1) Ever treated pulmonary MAC disease (2) Impossibe for evaluation for drug efficacy (3) pregnant, breat-feeding, possible pregant woman (4) allergy for AHCC (5) Inappropriate by decision of attending physician

Design outcomes

Primary

Measure	Time frame
safety (Adeverse event at 2 weeks, 2 months, 4 months, and 6 months after start of AHCC)	—

Secondary

Measure	Time frame
efficacy (sputa examination, chest image, clinical symptom)	—

Countries

Japan

Contacts

Public ContactMasaki Fujita

Fukuoka University Hospital Resipiratory Medicine

mfujita@fukuoka-u.ac.jp092-801-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026